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Since the early studies of Deutsch (1), the non-selective muscarinic receptor antagonist sco-
polamine has been used as a drug that impairs memory performance in man. The notion that 
scopolamine could be used as a pharmacological model of age-associated memory impairment 
and dementia further strengthened the cholinergic hypothesis of geriatric memory dysfunction by 
Bartus et al. (2). Since then, a vast amount of studies applied this model to induce memory impair-
ments in young healthy subjects to model age-related memory disorders. At present, scopolamine 
is still considered to be the best model for inducing cognitive impairments in healthy subjects (3). 
Scopolamine is therefore used as a pharmacological model to test novel cognition-enhancing drugs 
in animals [e.g., Ref. (4–6)] and in humans [e.g., Ref. (7, 8)]. In clinical trials, scopolamine is in 
particular being used as a model for AD in which novel cognition-enhancing drugs are tested (see 
https://ClinicalTrials.gov).
Further efforts have been made to compare human and animal data with scopolamine to further 
validate the scopolamine as a model of cognitive impairments. For example, comparable tests were 
developed for humans and animals to allow cross-species comparison [e.g., Ref. (9, 10)]. Another 
effort is comparing scopolamine effects on brain imaging parameters (11, 12). These studies reveal 
great cross-species similarities in the effects of scopolamine in comparable cognitive tasks in humans 
and animals, and that the effects on central blood flow is also comparable. These studies have resulted 
in a huge database in which the effects of scopolamine on cognitive and non-cognitive functions have 
been documented. This also relates to doses and routes of administration. Furthermore, interactions 
with various other drugs (also non-cholinergic) have been documented, which supports the notion 
of drug interactions in memory functions. Taken together, scopolamine is considered as a golden 
standard for cholinergic deficits and the existing data were used as a reference for evaluating novel 
cognition-enhancing drugs.
Although scopolamine has this established (gold standard) status, there are also some important 
issues related with this drug. A first point is that scopolamine is binding to both peripheral and 
central muscarinic receptors [see Ref. (13)]. Thus, scopolamine binds to all five different muscarinic 
receptors which are located in the brain as well in the peripheral system. This may relate to the various 
side effects that can occur after administration of scopolamine. Typical side effects are: dry mouth 
or throat, dizziness, drowsiness, fatigue, nausea, light-headedness, and blurred vision [e.g., Ref. (9)]. 
A careful analytic review on the effects of scopolamine in animals has shown that scopolamine at low 
doses mainly affects attentional functions and that memory performance is only affected at higher 
doses [see Ref. (13)]. Moreover, at relative low doses, typical side effects (increased omissions and 
latencies in responding) can be observed in rodents that may have an impact on performance in 
memory tasks.
In humans, similar effects on sedation have been observed, but it has been suggested that these 
effects could be dissociated from the effects on memory impairments [see Ref. (14)]. Interestingly, 
these effects seem to be dependent on the route of administration. Thus, intramuscular or intra-
venous administration has shown robust effects on memory performance (3), accompanied with 
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sedative effects. However, oral administration of scopolamine 
has resulted in sedative effects but in the absence of memory 
impairments (15, 16). Interestingly, the effects of intranasal 
scopolamine have also been investigated on side effects and 
cognitive performance (17, 18). This generally leads to a faster 
brain penetration and may have a stronger effect on brain func-
tion. Notably, no effects were found on cognition, and only some 
side effects were reported. However, it could be argued that the 
dose was too low (0.4 mg) or brain penetration was too fast in 
order to affect cognitive performance. Unfortunately, no plasma 
concentrations can be measured after intranasal administra-
tion, which makes it difficult comparing this with other routes 
of administration. Apparently, the effects of scopolamine on 
sedation are found in most clinical studies, whereas the effects 
on cognition are reported in fewer studies. Some experimental 
studies explicitly investigated the relation between sedation 
and cognition by comparing the effects of scopolamine and 
benzodiazepines (GABAA agonist). In one study, the effects of 
scopolamine and lorazepam on cognition and sedation could 
not be separated (19). However, the effect of scopolamine and 
lorazepam can be separated on encoding processes, as shown in 
a repetitive priming paradigm (20). Another study also showed 
a differential effect of lorazepam and scopolamine on attention 
and working memory (21). Thus, the effects of benzodiazepines 
and scopolamine on arousal may be similar, but the effects on 
cognitive functions can be differentiated if specific tasks are used.
A subsequent study was able to show a one-sided dissociation 
between sedation and cognitive impairment (22). In this study, 
the effects of an H1 receptor antagonist (diphenhydramine) were 
compared with lorazepam and scopolamine. All drugs affected 
arousal but only scopolamine and lorazepam impaired memory. 
These findings were supported by the drug effects on EEG meas-
ures and indicate that the effects on arousal and memory were 
not interdependent. Although different studies suggest a differ-
entiation between drug effects on arousal and memory (19, 22), 
a drug that only impairs cognitive functions and not the arousal 
state would be preferable. Moreover, this would show a double 
dissociation between arousal and memory performance (22).
Although the literature has shown robust effects of scopola-
mine on word learning (episodic memory task), some reported 
findings may suggest something else. Thus, scopolamine had a 
larger effect on immediate and delayed recall when presentation 
rate was fast (i.e., 1 word per 2 s), whereas it had only a marginal 
effect when presentation rate was 1 word per 5 s (23). The effects 
of scopolamine on word learning seem to be dependent on 
the pace of the task, which is related to the presentation time, 
inter-stimulus interval, and response-stimulus interval. These 
parameters are of key importance, whether attentional circuits in 
the brain are triggered. The faster the pace, the more declarative 
memory performance will become dependent on attentional 
constraints [or in essence, time constraints; see Ref. (24)]. Taken 
together, these findings suggest that the separation between 
arousal/attention and memory effects may not be easy to establish 
and require more variation of experimental parameters before 
this can be demonstrated.
As mentioned earlier, scopolamine is assumed to model the 
impaired cholinergic neurotransmission in AD. However, more 
recent studies have also shown other characteristic features 
of brain dysfunction in AD and the scopolamine model. For 
example, arterial spin labeled perfusion MRI studies have shown 
hypoperfusion mainly in the temporal lobe regions of AD patients 
(25, 26). In contrast, scopolamine has been found to mainly 
reduce cerebral blood flow in frontal areas (27–29). Although it 
may be questioned to what extend reduced blood flow in specific 
brain regions may relate to specific cognitive functions, these data 
do not support a strong face/predictive validity for scopolamine 
with respect to brain blood flow and the site of action in the 
brain. Although the above may caution the use of scopolamine as 
a model for memory impairment, scopolamine still is the golden 
standard for this purpose. The main advantage is that this drug 
is well characterized and there is enormous database to which 
the effects with new treatments can be compared with. For these 
reasons, it is obvious that scopolamine still will be used as a drug 
to induce memory impairments in animals and humans to model 
aging/AD-related memory dysfunctions.
Interestingly, a more specific cholinergic memory deficit 
model has been proposed based on selectivity of muscarinic 
receptors. Both the M1 and M2 receptors have been indicated as 
relevant for cognition, but most research has focused on the M1 
receptor (30). It has been shown that the M1 receptor is more 
specifically located in cortical and hippocampal structures and 
that its expression in the body is limited [see Ref. (13)]. Moreover, 
the M1 receptor has been indicated to be related to cognitive 
deficits in AD (31, 32). Therefore, it has been suggested that 
blocking the M1 receptor could be regarded as a better model for 
age-associated and dementia-related memory deficits (13, 33). 
Biperiden, which is clinically used to reduce motor symptoms 
in Parkinson’s disease, is a relative selective muscarinic type 1 
(M1) antagonist (34), and could be used as a drug to evaluate 
the effects on memory. Two human studies have shown selec-
tive effects of biperiden treatment on memory performance 
with only limited side effects (35, 36). A noteworthy feature of 
the postsynaptic M1 receptor is that an antagonist can impair 
memory performance and that an agonist can improve perfor-
mance. Thus, the M1 receptor is also considered as a target to 
improve memory functions (37, 38). Various M1 agonists have 
been developed as drugs to improve memory performance in 
dementia and schizophrenia (39). One of the first (orthosteric) 
M1 agonist that showed efficacy in Alzheimer patients and 
schizophrenics was xanomeline (40, 41). However, this drug was 
not very selective for the M1 receptor and associated with dose-
limiting side effects and was therefore not further developed. 
More recently, positive allosteric modulators (PAMs) have been 
developed which are more selective for the M1 receptor. One 
study in monkeys showed that an M1 positive allosteric modula-
tor (PAM) improved the performance in an object detour test 
(42). Another study in humans showed that a PAM of the M1 
receptor improved memory functions in a nicotine abstinence 
model (43). Taken together, the M1 receptor can be regarded as 
an interesting specific target for memory modulation.
The main mechanism by which M1 receptors can impair or 
improve memory is obviously via the cholinergic neurotransmis-
sion. However, additional mechanisms of action of M1 receptors 
have been described. For example, an in  vitro study showed 
3Blokland et al. M1 Antagonism for Memory Impairment
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 167
that blocking the M1 receptor decreases dendritic long-term 
potentiation (LTP) in the CA1 region of the hippocampus (44). 
Conversely, activation of the M1 receptors enhances LTP in the 
hippocampus (45). These effects are mediated by a co-localization 
of M1 and NMDA receptors and that activation of M1 receptors 
leads to enhanced NMDA receptor currents (46). This bidirec-
tional modulation of LTP by M1 receptor modulation supports 
the notion that, aside from a cholinergic mechanism, LTP is also 
involved in the modulating the memory effects. It should be noted 
that the M1 receptor is also located in medium spiny neurons, 
where they are involved in neuronal plasticity and involved in 
motor functions (47). There are also studies showing that block-
ing the M1 receptors may affect more complex motor behavior 
[e.g., Ref. (48, 49)]. Actually, the M1 receptor antagonist biperiden 
was developed for this purpose. Although modulation of the 
M1 receptor in this structure may contribute to the behavioral 
effects of drugs that affect this receptor, it has been shown that the 
strongest effects of allosteric agonist were most pronounced in 
the hippocampus and to a lesser extend in the striatum (50). This 
may suggest that M1 drugs predominantly affect hippocampal-
related functions. Along this line, the prescription of biperiden 
reports that amongst its side effects is memory loss. Moreover, 
this may further support the use of M1 antagonists as a model for 
selective memory impairment.
In summary, although scopolamine is being used to induce 
memory impairments in human subjects some aspects of this 
drug may caution the use of this drug to specifically impair 
memory performance. M1 antagonism can impair memory 
more specifically and M1 agonism (more specifically, PAMs) can 
improve memory. This strongly supports the notion that the M1 
receptor is highly relevant and specific for memory. The use of M1 
antagonist may offer a good alternative but more data are needed 
to support this claim.
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